Recommended
More Related Content
Viewers also liked
Viewers also liked (20)
Similar to Controversia tratamiento dislipemias
Similar to Controversia tratamiento dislipemias (20)
Recently uploaded
Recently uploaded (20)
Controversia tratamiento dislipemias
- 2. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (November 2013) GRUPO 1.- ENFERMEDAD CARDIOVASCULAR: ALTA INTENSIDAD SI EDAD < 75 A. MODERADA INTENSIDAD SI > 75 A. Trat. Alta-Intensidad con Estatinas Atorvastatin (40†)–80 mg Rosuvastatin 20 (40) mg GRUPO 2.- PACIENTES CON LDL > 190 mg / ml ALTA INTENSIDAD GRUPO 3.- DIABETICOS DE 40-75 a. LDL 70-189 ALTA INTENSIDAD SI RCV > 7,5 % INTENSIDAD MODERADA SI RCV < 7,5 % GRUPO 4.-PACIENTES LDL >70 mg% Y RCV >7,5 % ALTA INTENSIDAD CON RCV > 7,5 % MODERADA INTENSIDAD 5-7,5 % Trat. Moderada Intensidad Estatinas Atorvastatin 10 (20) mg Rosuvastatin (5) 10 mg Simvastatin 20–40 mg‡ Pravastatin 40 (80) mg Lovastatin 40 mg Fluvastatin XL 80 mg Fluvastatin 40 mg bid Pitavastatin 2–4 mg
- 3. In an article published November 18, 2013 in the New York Times , two physicians testing the accuracy of the new risk calculator developed by the American College of Cardiology(ACC) and American Heart Association (AHA) found that it vastly overestimated patient risk. Drs Paul Ridker and Nancy Cook (Brigham and Women's Hospital, Boston, MA) calculated the 10-year risk of cardiovascular events in three large-scale primary prevention cohorts— the Women's Health Study(WHS), the Physicians' Health Study (PHS), and theWomen's Health Initiative Observational Study (WHI-OS)—”SOBRESTIMA RCV ENTRE EL 75% AL 150%” EL
- 7. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) European Heart Journal Advance Access published May 3, 2012